PMID- 21821462
OWN - NLM
STAT- MEDLINE
DCOM- 20120120
LR  - 20220408
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 47
IP  - 10
DP  - 2011 Oct
TI  - TRB3 overexpression due to endoplasmic reticulum stress inhibits AKT kinase 
      activation of tongue squamous cell carcinoma.
PG  - 934-9
LID - 10.1016/j.oraloncology.2011.06.512 [doi]
AB  - Our investigation aims to evaluate the significance of TRB3, an endoplasmic 
      reticulum stress (ERS)-inducible gene, and explore its relationship with AKT in 
      oral tongue squamous cell carcinoma (OTSCC). Expression of TRB3 and 
      phosphorylated AKT (p-AKT) in OTSCC tissues and adjacent normal tissues were 
      assessed by RT-PCR, Western blot and immunohistochemistry assay. Correlation of 
      TRB3 and AKT was validated by TRB3 adenovirus plasmid (Ad-TRB3) transfection and 
      short hairpin RNA (shRNA) inhibition. The mRNA expression of TRB3 was 
      significantly higher than adjacent noncancerous tissues by RT-PCR in 15 of 18 
      specimens of OTSCC (83.3%, P<0.01). Both of TRB3 and AKT were highly expressed in 
      13 of 18 (72.2%) specimens of OTSCC comparing with adjacent noncancerous tissues 
      by Western blot assay (P<0.05). TRB3 was significantly elevated in 49.2% (63/128) 
      of pathologically confirmed specimens and 13.3% (4/30) of adjacent noncancerous 
      specimens by immunohistochemical analysis (P<0.01). TRB3 overexpression was 
      closely correlated with tumor pathological T stage, lymph node metastasis and 
      tumor recurrence. In addition, both mRNA and protein expression of TRB3 was 
      increased under thapsigargin (TG) or tunicmycin (TU)-induced ERS in Tca8113 and 
      CAL-27 cells. Moreover, expression of p-AKT protein decreased when Ad-TRB3 was 
      transected with OTSCC Tca8113 cells. However, expression of p-AKT protein 
      increased when TRB3 was inhibited by TRB3 shRNA inhibition. TRB3 expression was 
      closely correlated with OTSCC prognosis. Under ERS, TRB3 was up-regulated, 
      resulting in inhibiting the activation of AKT in OTSCC.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming 
      Medical University, Kunming 650118, China.
FAU - Wen, Hao-jie
AU  - Wen HJ
FAU - Guo, Zhu-ming
AU  - Guo ZM
FAU - Zeng, Mu-sheng
AU  - Zeng MS
FAU - Li, Man-zhi
AU  - Li MZ
FAU - Jiang, Yu-e
AU  - Jiang YE
FAU - He, Xiao-guang
AU  - He XG
FAU - Sun, Chuan-zheng
AU  - Sun CZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110806
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Antiviral Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Repressor Proteins)
RN  - 0 (TRIB3 protein, human)
RN  - 11089-65-9 (Tunicamycin)
RN  - 67526-95-8 (Thapsigargin)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Antiviral Agents/pharmacology
MH  - Biomarkers, Tumor
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cell Cycle Proteins/genetics/*metabolism
MH  - Endoplasmic Reticulum Stress/*physiology
MH  - Enzyme Inhibitors/pharmacology
MH  - Female
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/metabolism/pathology
MH  - Phosphorylation
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - RNA, Small Interfering/antagonists & inhibitors
MH  - Repressor Proteins/genetics/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Thapsigargin/pharmacology
MH  - Tongue Neoplasms/*metabolism/pathology
MH  - Tunicamycin/pharmacology
EDAT- 2011/08/09 06:00
MHDA- 2012/01/21 06:00
CRDT- 2011/08/09 06:00
PHST- 2011/04/25 00:00 [received]
PHST- 2011/06/19 00:00 [revised]
PHST- 2011/06/25 00:00 [accepted]
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2012/01/21 06:00 [medline]
AID - S1368-8375(11)00753-6 [pii]
AID - 10.1016/j.oraloncology.2011.06.512 [doi]
PST - ppublish
SO  - Oral Oncol. 2011 Oct;47(10):934-9. doi: 10.1016/j.oraloncology.2011.06.512. Epub 
      2011 Aug 6.